Skip to main content
SpringerLink
Log in

Membranous nephropathy complicated by immune thrombocytopenia treated with low-density lipoprotein apheresis: a case report and literature review

  • Case Report
  • Published:
CEN Case Reports Aims and scope Submit manuscript

Abstract

Immune thrombocytopenia (ITP) may lead to membranous nephropathy (MN). Here, we report a case of MN complicated by ITP and validate the hypothesis that circulating antiplatelet antibodies cause MN using immunofluorescence analysis for immunoglobulin (Ig) G subclass and anti-phospholipase A2 receptor (PLA2R) antibodies. A 39-year-old Japanese man with ITP, who had been treated with prednisolone for 10 months, achieved a stable disease condition. However, 4 months after tapering the dose down to 10 mg prednisolone, he developed nephrotic syndrome, with a urinary protein-to-creatinine ratio (U-PCR) of 10.6 g/g Cr and was admitted to our hospital. His platelet count, at 89,000/μL, was lower than the normal range, indicating the recurrence of ITP. Renal biopsy revealed the thickening of the glomerular basement membrane with the deposition of IgG and complement component 3. Predominant deposition of IgG1 and negativity for anti-PLA2R staining indicated secondary MN; however, no typical conditions of secondary MN were evident. Although oral prednisolone and cyclosporine A were administered, he was refractory to treatment. A total of 12 sessions of low-density lipoprotein apheresis (LDL-A) decreased his U-PCR to < 3 g/g Cr. Seven months after discharge, his U-PCR further decreased to 0.54 g/g Cr and platelet count recovered to > 200,000/μL. Our literature review reveals that this condition is refractory to steroid therapy. LDL-A can be an effective treatment in drug-resistant MN complicated by ITP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Yokoyama H, Taguchi T, Sugiyama H, Sato H, Committee for the Standardization of Renal Pathological Diagnosis and for Renal Biopsy and Disease Registry in the Japanese Society of Nephrology. Membranous nephropathy in Japan: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2012;16:557–63. https://doi.org/10.1007/s10157-012-0593-7.

    Article  PubMed  Google Scholar 

  2. Ronco P, Debiec H. Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. J Am Soc Nephrol. 2005;16:1205–13. https://doi.org/10.1681/asn.2004121080.

    Article  CAS  PubMed  Google Scholar 

  3. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006;133:364–74. https://doi.org/10.1111/j.1365-2141.2006.06024.x.

    Article  CAS  PubMed  Google Scholar 

  4. Robles NR, Lopez Gomez JM, Lobos JM, Valderrabano F. Membranous glomerulonephritis associated with idiopathic thrombocytopenic purpura. Rev Clin Esp. 1989;185:402–4 (PMID: 2623266).

    CAS  PubMed  Google Scholar 

  5. Tamura K, Takagi N, Yabana M, Kihara M, Toya Y, Takizawa T, et al. Nephrotic syndrome due to membranous glomerulonephritis in a patient with idiopathic thrombocytopenic purpura. Nephron. 1999;82:87–9. https://doi.org/10.1159/000045379.

    Article  CAS  PubMed  Google Scholar 

  6. Kano K, Ito S, Ando T, Arisaka O, Tomita S, Ueda Y. Chronic idiopathic thrombocytopenic purpura in a patient with membranous glomerulonephritis. Nephron. 1999;83:358. https://doi.org/10.1159/000045428.

    Article  CAS  PubMed  Google Scholar 

  7. Lande MB, Thomas GA, Houghton DC. Membranous nephropathy associated with chronic immune thrombocytopenic purpura in childhood. Am J Kid Dis. 2001;37:E40. https://doi.org/10.1016/s0272-6386(05)90004-8.

    Article  CAS  PubMed  Google Scholar 

  8. Alkindi S, Khan S, Riyami D, Farooqi M, Pathare A. Coexistence of immune thrombocytopenic purpura and idiopathic membranous glomerulonephritis successfully treated with rituximab. Platelets. 2010;21:575–7. https://doi.org/10.3109/09537104.2010.494744.

    Article  CAS  PubMed  Google Scholar 

  9. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21. https://doi.org/10.1056/nejmoa0810457.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ohtani H, Wakui H, Komatsuda A, Okuyama S, Masai R, Maki N, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant. 2004;19:574–9. https://doi.org/10.1093/ndt/gfg616.

    Article  CAS  PubMed  Google Scholar 

  11. Muso E. Beneficial effect of LDL-apheresis in refractory nephrotic syndrome. Clin Exp Nephrol. 2014;18:286–90. https://doi.org/10.1007/s10157-013-0930-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Muso E, Mune M, Hirano T, Hattori M, Kimura K, Watanabe T, et al. Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study. Clin Exp Nephrol. 2015;19:379–86. https://doi.org/10.1007/s10157-014-0996-8.

    Article  CAS  PubMed  Google Scholar 

  13. Chan H, Moore JC, Finch CN, Warkentin TE, Kelton JG. The IgG subclasses of platelet-associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2003;122:818–24. https://doi.org/10.1046/j.1365-2141.2003.04509.x.

    Article  CAS  PubMed  Google Scholar 

  14. Pfueller SL, Firkin BG, Kerlero de Rosbo N, Riglar A, Mackay IR. Association of increased immune complexes, platelet IgG and serum IgG in chronic active hepatitis. Clin Exp Immunol. 1983;54:655–60 (PMID: 6652974; PMCID: PMC1536157).

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982;2:1309–11. https://doi.org/10.1016/s0140-6736(82)91513-6.

    Article  CAS  PubMed  Google Scholar 

  16. Stefanutti C, Mazza F, Pasqualetti D, Di Giacomo S, Watts GF, Massari MS, et al. Lipoprotein apheresis downregulates IL-1α, IL-6 and TNF-α mRNA expression in severe dyslipidaemia. Atheroscler Suppl. 2017;30:200–8. https://doi.org/10.1016/j.atherosclerosissup.2017.05.028.

    Article  PubMed  Google Scholar 

  17. Talaat RM, Elmaghraby AM, Barakat SS, El-Shahat M. Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP). Clin Exp Immunol. 2014;176:291–300. https://doi.org/10.1111/cei.12279.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Zhao Y, Xu P, Guo L, Wang H, Min Y, Feng Q, et al. Tumor necrosis factor-α blockade corrects monocyte/macrophage imbalance in primary immune thrombocytopenia. Thromb Haemost. 2021;121:767–81. https://doi.org/10.1055/s-0040-1722186.

    Article  PubMed  Google Scholar 

  19. Stefanutti C, Morozzi C, Petta A. Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia. Cytokine. 2011;56:842–9. https://doi.org/10.1016/j.cyto.2011.08.027.

    Article  CAS  PubMed  Google Scholar 

  20. Di Paola A, Palumbo G, Merli P, Argenziano M, Tortora C, Strocchio L, et al. Effects of eltrombopag on in vitro macrophage polarization in pediatric immune thrombocytopenia. Int J Mol Sci. 2020;22:97. https://doi.org/10.3390/ijms22010097.

    Article  CAS  PubMed Central  Google Scholar 

  21. Ueda S, Sugimoto K, Yanagida H, Fujita S, Miyazawa T, Sakata N, et al. Low-density lipoprotein adsorption therapy can restore drug sensitivity for immunosuppressants via inhibitory effects upon MDR-1 gene expression. Ther Apher Dial. 2011;15:499–503. https://doi.org/10.1111/j.1744-9987.2011.00984.x.

    Article  CAS  PubMed  Google Scholar 

  22. Wasilewska A, Zoch-Zwierz W, Pietruczuk M, Zalewski G. Expression of P-glycoprotein in lymphocytes from children with nephrotic syndrome, depending on their steroid response. Pediatr Nephrol. 2006;21:1274–80. https://doi.org/10.1007/s00467-006-0187-2.

    Article  PubMed  Google Scholar 

  23. Schwarzová L, Pirník Z, Štecová N. Idiopathic thrombocytopenia refractery to therapy of cyclosporine A in clinical practice—case report. Ceska Slov Farm. 2018;66:233–7 (PMID: 29623717).

    PubMed  Google Scholar 

  24. Biancone L, Andres G, Ahn H, DeMartino C, Stamenkovic I. Inhibition of the CD40-CD40ligand pathway prevents murine membranous glomerulonephritis. Kidney Int. 1995;48:458–68. https://doi.org/10.1038/ki.1995.314.

    Article  CAS  PubMed  Google Scholar 

  25. Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 2017;13:563–79. https://doi.org/10.1038/nrneph.2017.92.

    Article  CAS  PubMed  Google Scholar 

  26. Patel VL, Mahévas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119:5989–95. https://doi.org/10.1182/blood-2011-11-393975.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381:36–46. https://doi.org/10.1056/nejmoa1814427.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

No funding was received for this study.

Author information

Authors and Affiliations

  1. Department of Nephrology, Asahikawa Red Cross Hospital, 1jo 1 chome, Akebono, Asahikawa, Hokkaido, Japan

    Keitaro Nishizawa, Tomohisa Yamashita & Hironori Kobayashi

  2. Hokkaido Renal Pathology Center, Sapporo, Japan

    Yayoi Ogawa

Authors
  1. Keitaro Nishizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomohisa Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yayoi Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hironori Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keitaro Nishizawa.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Research involving human participants (Ethical approval)

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number: 202046-3) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Written informed consent was obtained from the patient for the publication of this case report.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nishizawa, K., Yamashita, T., Ogawa, Y. et al. Membranous nephropathy complicated by immune thrombocytopenia treated with low-density lipoprotein apheresis: a case report and literature review. CEN Case Rep 11, 43–49 (2022). https://doi.org/10.1007/s13730-021-00630-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13730-021-00630-w

Keywords

Search

Navigation